Large-scale preparation of liquid cell culture media and buffers for biopharmaceutical manufacturing has been discussed for decades, but only recently have the economics changed enough to warrant outsourcing of this process1.  As expectations for manufacturing efficiency increase, we are likely to see more events like Amgen’s recent reduction in manufacturing operations by 23%, and its plans to cut up to 15% of its manufacturing and R&D workforce. This, and similar cuts are evidence of the p...